Literature DB >> 8543501

Efficacy of meropenem in experimental meningitis.

K Nairn1, G L Shepherd, J R Edwards.   

Abstract

Meropenem and comparator antibiotics, including ceftriaxone, ceftazidime, benzyl penicillin and a combination of ampicillin plus gentamicin, were evaluated in a model of bacterial meningitis in the guinea-pig. The model is an acute infection in which challenge with each organism, if untreated, causes an increase in numbers of white blood cells, elevation of protein concentrations and 6-8 log10 cfu/mL of bacteria in the CSF. Infections caused by Haemophilus influenzae, Neisseria meningitidis, three strains of Streptococcus pneumoniae (two penicillin-resistant), Escherichia coli, Pseudomonas aeruginosa and Listeria monocytogenes all responded to meropenem, which was as active as the comparator agents in all studies, and was more active in most. Of particular note were the results seen against S. pneumoniae (penicillin-resistant) infections, in which meropenem was significantly more effective than ceftriaxone. Also notable were results from the P. aeruginosa infection where meropenem, at low doses, was more effective than ceftazidime. Activity against L. monocytogenes was equivalent to that produced by treatment with the combination of ampicillin plus gentamicin, even when treatment was delayed. These results show that, in an animal model, meropenem penetrates into CSF in concentrations sufficient to produce significant reductions in the numbers of common and less common pathogens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8543501     DOI: 10.1093/jac/36.suppl_a.73

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meningitis.

Authors:  F Fitoussi; C Doit; K Benali; S Bonacorsi; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  Experimental study of meropenem in the therapy of cephalosporin-susceptible and -resistant pneumococcal meningitis.

Authors:  E Force; F Taberner; C Cabellos; S Ribes; A Domenech; F Tubau; P F Viladrich; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-04-02       Impact factor: 3.267

3.  Meropenem therapy failure in Listeria monocytogenes infection.

Authors:  S Stepanović; G Lazarević; M Jesić; R Kos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-05-13       Impact factor: 3.267

4.  Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy.

Authors:  R Nau; C Lassek; M Kinzig-Schippers; A Thiel; H W Prange; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

5.  Evaluation of meropenem alone and combined with rifampin in the guinea pig model of pneumococcal meningitis.

Authors:  E Force; F Taberner; C Cabellos; S Ribes; A Doménech; F Tubau; P F Viladrich; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-02-17       Impact factor: 3.267

Review 6.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.